source
- FDA releases draft guidance to trim animal testing in cancer drug developmentThe FDA's Oncology Center of Excellence announced a draft guidance aimed at reducing unnecessary animal studies in the nonclinical safety assessment of certain oncology drugs. The guidance suggest…
- Allogene CEO David Chang to step down after eight years; former Esperion chief joins PhlowLongtime Allogene chief executive David Chang announced he will leave the role at the end of June, concluding an eight‑year tenure leading the cell‑therapy developer. The company said a successor…